Immuron (IMRN) Income from Continuing Operations (2016 - 2024)
Immuron's quarterly Income from Continuing Operations came in at 1.660259165668942e+18 in Q4 2024, up 80082653894883.1% year-on-year from N/an in Q1 2024, and up 80082653894883.1% quarter-over-quarter from 2073182.0 in Q4 2023.
Immuron has reported Income from Continuing Operations for 9 years, with the latest figure at 1.660259165668942e+18 in Q4 2024.
- For the quarter ending Q4 2024, Income from Continuing Operations rose 80082653894883.1% year-over-year to 1.660259165668942e+18; the trailing twelve-month figure through Dec 2024 stood at 1.6602591656656172e+18 (up 49736690296018.12% YoY), and the FY2025 full-year result was 3380634.04, up 25.69% from the prior year.
- Income from Continuing Operations for Q4 2024 stood at 1.660259165668942e+18, up from 2073182.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 1.660259165668942e+18 in Q4 2024, with the low at 2073182.0 in Q4 2023.
- Average Income from Continuing Operations over 5 years is 2.7670986094425776e+17, with a median of 35292.09 recorded in 2021.
- Year-over-year, Income from Continuing Operations tumbled 15849.51% in 2023 and jumped 80082653894883.1% in 2024.
- Tracing IMRN's Income from Continuing Operations over 5 years: stood at 57387.72 in 2020, then soared by 77.0% to 13196.46 in 2021, then rose by 1.5% to 12998.41 in 2022, then plunged by 15849.51% to 2073182.0 in 2023, then jumped by 80082653894883.1% to 1.660259165668942e+18 in 2024.
- The last three Income from Continuing Operations figures came in at 1.660259165668942e+18 (Q4 2024), 2073182.0 (Q4 2023), and 1238720.54 (Q2 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Immuron | 1.27 Bn | 1.27 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 1,660,259,165.67 Bn |
| Dec 31, 2023 | -2.07 Mn |
| Jun 30, 2023 | -1.24 Mn |
| Dec 31, 2022 | -12,998.41 |
| Dec 31, 2021 | -13,196.46 |
| Dec 31, 2020 | -57,387.72 |
| Dec 31, 2019 | -15,212.27 |
| Dec 31, 2018 | -1.58 Mn |
| Dec 31, 2017 | 3.84 Mn |
| Dec 31, 2016 | 2.56 Mn |
| Jun 30, 2016 | -3.28 Mn |